Beigene Ltd (NASDAQ:BGNE) Director Donald W. Glazer sold 41,463 shares of the business’s stock in a transaction that occurred on Wednesday, September 28th. The shares were sold at an average price of $30.66, for a total value of $1,271,255.58. Following the transaction, the director now owns 4,881,997 shares of the company’s stock, valued at approximately $149,682,028.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Shares of Beigene Ltd (NASDAQ:BGNE) opened at 30.81 on Friday. The stock’s market cap is $1.01 billion. The company has a 50 day moving average price of $29.97 and a 200-day moving average price of $29.07. Beigene Ltd has a one year low of $22.51 and a one year high of $35.60.
Beigene (NASDAQ:BGNE) last released its quarterly earnings data on Wednesday, August 10th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by $0.05. The business had revenue of $0.40 million for the quarter, compared to the consensus estimate of $2.08 million. The firm’s quarterly revenue was down 71.4% compared to the same quarter last year. Equities analysts predict that Beigene Ltd will post ($3.38) earnings per share for the current fiscal year.
Several brokerages have issued reports on BGNE. Cowen and Company restated a “buy” rating on shares of Beigene in a research report on Monday, June 6th. Zacks Investment Research upgraded Beigene from a “sell” rating to a “hold” rating in a research report on Monday, September 12th. Finally, Maxim Group began coverage on Beigene in a research report on Wednesday, September 21st. They set a “buy” rating and a $41.00 target price for the company. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Beigene currently has an average rating of “Buy” and a consensus target price of $40.00.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Boxer Capital LLC increased its position in shares of Beigene by 18.4% in the second quarter. Boxer Capital LLC now owns 493,630 shares of the company’s stock valued at $14,710,000 after buying an additional 76,751 shares during the period. Vident Investment Advisory LLC purchased a new position in shares of Beigene during the second quarter valued at $678,000. FMR LLC increased its position in shares of Beigene by 34.0% in the second quarter. FMR LLC now owns 2,300,337 shares of the company’s stock valued at $68,550,000 after buying an additional 583,277 shares during the period. Board of Trustees of The Leland Stanford Junior University purchased a new position in shares of Beigene during the second quarter valued at $1,490,000. Finally, BlackRock Institutional Trust Company N.A. increased its position in shares of Beigene by 67.9% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 6,404 shares of the company’s stock valued at $191,000 after buying an additional 2,589 shares during the period.
Beigene Company Profile
BeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton’s tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas.
Receive News & Ratings for Beigene Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene Ltd and related companies with MarketBeat.com's FREE daily email newsletter.